51
|
Mohapatra RK, Kandi V, Mishra S, Sarangi AK, Pradhan MK, Mohapatra PK, Behera A, Dhama K. Emerging novel sub-lineage BA.2.75: The next dominant omicron variant? Int J Surg 2022; 104:106835. [PMID: 35963574 DOI: 10.1016/j.ijsu.2022.106835] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Accepted: 08/09/2022] [Indexed: 11/15/2022]
Affiliation(s)
- Ranjan K Mohapatra
- Department of Chemistry, Government College of Engineering, Keonjhar, 758002, Odisha, India.
| | - Venkataramana Kandi
- Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, 505417, Telangana, India
| | - Snehasish Mishra
- School of Biotechnology, Campus-11, KIIT Deemed-to-be-University, Bhubaneswar, Odisha, 751024, India
| | - Ashish K Sarangi
- Department of Chemistry, School of Applied Sciences, Centurion University of Technology and Management, Odisha, India
| | - Manoj Kumar Pradhan
- Department of Chemistry, Government College of Engineering, Keonjhar, 758002, Odisha, India
| | - Pranab K Mohapatra
- Department of Chemistry, C. V. Raman Global University, Bhubaneswar, Odisha, India
| | - Ajit Behera
- Department of Metallurgical & Materials Engineering, National Institute of Technology, Rourkela, 769008, India
| | - Kuldeep Dhama
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, 243122, India
| |
Collapse
|
52
|
Mohapatra RK, Kandi V, Tuli HS, Chakraborty C, Dhama K. The recombinant variants of SARS-CoV-2: Concerns continues amid COVID-19 pandemic. J Med Virol 2022; 94:3506-3508. [PMID: 35419806 PMCID: PMC9088633 DOI: 10.1002/jmv.27780] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2022] [Revised: 04/10/2022] [Accepted: 04/11/2022] [Indexed: 11/30/2022]
Affiliation(s)
| | - Venkataramana Kandi
- Department of MicrobiologyPrathima Institute of Medical SciencesKarimnagarTelanganaIndia
| | - Hardeep S. Tuli
- Department of BiotechnologyMaharishi Markandeshwar UniversityMullanaHaryanaIndia
| | | | - Kuldeep Dhama
- Division of PathologyICAR‐Indian Veterinary Research InstituteBareillyIndia
| |
Collapse
|
53
|
Antonopoulou I, Sapountzaki E, Rova U, Christakopoulos P. The Inhibitory Potential of Ferulic Acid Derivatives against the SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics, and ADMET Evaluation. Biomedicines 2022; 10:biomedicines10081787. [PMID: 35892687 PMCID: PMC9329733 DOI: 10.3390/biomedicines10081787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 07/19/2022] [Accepted: 07/21/2022] [Indexed: 11/16/2022] Open
Abstract
The main protease (Mpro) of SARS-CoV-2 is an appealing target for the development of antiviral compounds, due to its critical role in the viral life cycle and its high conservation among different coronaviruses and the continuously emerging mutants of SARS-CoV-2. Ferulic acid (FA) is a phytochemical with several health benefits that is abundant in plant biomass and has been used as a basis for the enzymatic or chemical synthesis of derivatives with improved properties, including antiviral activity against a range of viruses. This study tested 54 reported FA derivatives for their inhibitory potential against Mpro by in silico simulations. Molecular docking was performed using Autodock Vina, resulting in comparable or better binding affinities for 14 compounds compared to the known inhibitors N3 and GC376. ADMET analysis showed limited bioavailability but significantly improved the solubility for the enzymatically synthesized hits while better bioavailability and druglikeness properties but higher toxicity were observed for the chemically synthesized ones. MD simulations confirmed the stability of the complexes of the most promising compounds with Mpro, highlighting FA rutinoside and compound e27 as the best candidates from each derivative category.
Collapse
|
54
|
Dadras O, SeyedAlinaghi S, Karimi A, Shojaei A, Amiri A, Mahdiabadi S, Fakhfouri A, Razi A, Mojdeganlou H, Mojdeganlou P, Barzegary A, Pashaei Z, Afsahi AM, Shobeiri P, Mehraeen E. COVID-19 Vaccines' Protection Over Time and the Need for Booster Doses; a Systematic Review. ARCHIVES OF ACADEMIC EMERGENCY MEDICINE 2022; 10:e53. [PMID: 36033989 PMCID: PMC9397599 DOI: 10.22037/aaem.v10i1.1582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Introduction Controversies existed regarding the duration of COVID-19 vaccines' protection and whether receiving the usual vaccine doses would be sufficient for long-term immunity. Therefore, we aimed to systematically review the studies regarding the COVID-19 vaccines' protection three months after getting fully vaccinated and assess the need for vaccine booster doses. Methods The relevant literature was searched using a combination of keywords on the online databases of PubMed, Scopus, Web of Science, and Cochrane on September 17th, 2021. The records were downloaded and the duplicates were removed. Then, the records were evaluated in a two-step process, consisting of title/abstract and full-text screening processes, and the eligible records were selected for the qualitative synthesis. We only included original studies that evaluated the efficacy and immunity of COVID-19 vaccines three months after full vaccination. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement to ensure the reliability of results. Results Out of the 797 retrieved records, 12 studies were included, 10 on mRNA-based vaccines and two on inactivated vaccines. The majority of included studies observed acceptable antibody titers in most of the participants even after 6 months; however,it appeared that the titers could also decrease in a considerable portion of people. Due to the reduction in antibody titers and vaccine protection, several studies suggested administering the booster dose, especially for older patients and those with underlying conditions, such as patients with immunodeficiencies. Conclusion Studies indicated that vaccine immunity decreases over time, making people more susceptible to contracting the disease. Besides, new variants are emerging, and the omicron variant is continuing to spread and escape from the immune system, indicating the importance of a booster dose.
Collapse
Affiliation(s)
- Omid Dadras
- Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran. ,School of Public Health, Walailak University, Nakhon Si Thammarat, Thailand
| | - SeyedAhmad SeyedAlinaghi
- Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
| | - Amirali Karimi
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Alireza Shojaei
- Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
| | - Ava Amiri
- Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
| | - Sara Mahdiabadi
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Armin Razi
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Paniz Mojdeganlou
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | - Zahra Pashaei
- Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
| | - Amir Masoud Afsahi
- Department of Radiology, School of Medicine, University of California, San Diego (UCSD), California, USA
| | - Parnian Shobeiri
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Esmaeil Mehraeen
- Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran. ,Corresponding Author:EsmaeilMehraeen, Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran. Postal Code: 5681761351, Tel: +98-45-32426801, Fax: +98-45-32422305, E-mail:
| |
Collapse
|
55
|
Ko Y, Mendoza VM, Mendoza R, Seo Y, Lee J, Lee J, Kwon D, Jung E. Multi-Faceted Analysis of COVID-19 Epidemic in Korea Considering Omicron Variant: Mathematical Modeling-Based Study. J Korean Med Sci 2022; 37:e209. [PMID: 35790210 PMCID: PMC9259245 DOI: 10.3346/jkms.2022.37.e209] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Accepted: 06/07/2022] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND The most recent variant of concern, omicron (B.1.1.529), has caused numerous cases worldwide including the Republic of Korea due to its fast transmission and reduced vaccine effectiveness. METHODS A mathematical model considering age-structure, vaccine, antiviral drugs, and influx of the omicron variant was developed. We estimated transmission rates among age groups using maximum likelihood estimation for the age-structured model. The impact of non-pharmaceutical interventions (NPIs; in community and border), quantified by a parameter μ in the force of infection, and vaccination were examined through a multi-faceted analysis. A theory-based endemic equilibrium study was performed to find the manageable number of cases according to omicron- and healthcare-related factors. RESULTS By fitting the model to the available data, the estimated values of μ ranged from 0.31 to 0.73, representing the intensity of NPIs such as social distancing level. If μ < 0.55 and 300,000 booster shots were administered daily from February 3, 2022, the number of severe cases was forecasted to exceed the severe bed capacity. Moreover, the number of daily cases is reduced as the timing of screening measures is delayed. If screening measure was intensified as early as November 24, 2021 and the number of overseas entrant cases was contained to 1 case per 10 days, simulations showed that the daily incidence by February 3, 2022 could have been reduced by 87%. Furthermore, we found that the incidence number in mid-December 2021 exceeded the theory-driven manageable number of daily cases. CONCLUSION NPIs, vaccination, and antiviral drugs influence the spread of omicron and number of severe cases in the Republic of Korea. Intensive and early screening measures during the emergence of a new variant is key in controlling the epidemic size. Using the endemic equilibrium of the model, a formula for the manageable daily cases depending on the severity rate and average length of hospital stay was derived so that the number of severe cases does not surpass the severe bed capacity.
Collapse
Affiliation(s)
- Youngsuk Ko
- Department of Mathematics, Konkuk University, Seoul, Korea
| | - Victoria May Mendoza
- Department of Mathematics, Konkuk University, Seoul, Korea
- Institute of Mathematics, University of the Philippines Diliman, Quezon City, Philippines
| | - Renier Mendoza
- Department of Mathematics, Konkuk University, Seoul, Korea
- Institute of Mathematics, University of the Philippines Diliman, Quezon City, Philippines
| | - Yubin Seo
- Division of Infectious Disease, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
| | - Jacob Lee
- Division of Infectious Disease, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
| | - Jonggul Lee
- Division of Public Health Emergency Response Research, Korea Disease Control and Prevention Agency, Cheongju, Korea
| | - Donghyok Kwon
- Division of Public Health Emergency Response Research, Korea Disease Control and Prevention Agency, Cheongju, Korea
| | - Eunok Jung
- Department of Mathematics, Konkuk University, Seoul, Korea.
| |
Collapse
|
56
|
Bazargan M, Elahi R, Esmaeilzadeh A. OMICRON: Virology, immunopathogenesis, and laboratory diagnosis. J Gene Med 2022; 24:e3435. [PMID: 35726542 PMCID: PMC9350010 DOI: 10.1002/jgm.3435] [Citation(s) in RCA: 26] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 06/01/2022] [Accepted: 06/09/2022] [Indexed: 12/19/2022] Open
Abstract
Since its emersion, coronavirus disease 2019 (COVID-19) has been a significant global dilemma. Several mutations in the severe acute respiratory virus (SARS-Co-2) genome has given rise to different variants with various levels of transmissibility, severity and mortality. Up until November 2021, the variants of concern declared by the World Health Organization were Alpha, Beta, Delta and Gamma. Since then, a novel variant named Omicron (B.1.1.529) has been developed. BA.1, BA.1.1, BA.2 and BA.3 are four known subvariants of Omicron. The Omicron variant involves new mutations in its spike protein, most of which are in its receptor binding site, and increase its transmissibility and decrease its antibody and vaccine response. Understanding the virology and mutations of Omicron is necessary for developing diagnostic and therapeutic methods. Moreover, important issues, such as the risk of re-infection, the response to different kinds of vaccines, the need for a booster vaccine dose and the increased risk of Omicron infection in pediatrics, need to be addressed. In this article, we provide an overview of the biological and immunopathological properties of Omicron and its subvariants, its clinical signs and symptoms, Omicron and pediatrics, vaccines against Omicron, re-infection with Omicron, diagnostic approaches and specific challenges of Omicron in the successful control and management of the rapid global spread of this variant.
Collapse
Affiliation(s)
- Mahsa Bazargan
- Department of Immunology, School of MedicineSahid Beheshti University of Medical SciencesTehranIran
- Virology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Masih Daneshvari HospitalSahid Beheshti University of Medical SciencesTehranIran
| | - Reza Elahi
- School of MedicineZanjan University of Medical SciencesZanjanIran
| | - Abdolreza Esmaeilzadeh
- Department of ImmunologyZanjan University of Medical SciencesZanjanIran
- Cancer Gene Therapy Research CenterZanjan University of Medical SciencesZanjanIran
| |
Collapse
|
57
|
Islam MR, Rahman MS, Qusar MMAS. Community-based decentralized mental health services are essential to prevent the epidemic turn of post-Covid mental disorders in Bangladesh: A call to action. Health Sci Rep 2022; 5:e734. [PMID: 35873400 PMCID: PMC9297297 DOI: 10.1002/hsr2.734] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 07/02/2022] [Accepted: 07/07/2022] [Indexed: 12/03/2022] Open
|
58
|
Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (Alpha) and B.1.617.2 (Delta) related to their pandemic response in UK and India. INFECTION, GENETICS AND EVOLUTION : JOURNAL OF MOLECULAR EPIDEMIOLOGY AND EVOLUTIONARY GENETICS IN INFECTIOUS DISEASES 2022; 101:105282. [PMID: 35427787 PMCID: PMC9005225 DOI: 10.1016/j.meegid.2022.105282] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 04/04/2022] [Accepted: 04/08/2022] [Indexed: 02/07/2023]
Abstract
Background The massive increase in COVID-19 infection had generated a second wave in India during May–June 2021 with a critical pandemic situation. The Delta variant (B.1.617.2) was a significant factor during the second wave. Conversely, the UK had passed through the crucial phase of the pandemic from November to December 2020 due to B.1.1.7. The study tried to comprehend the pandemic response in the UK and India to the spread of the B.1.1.7 (Alpha, UK) variant and B.1.617.2 (Delta, India) variant. Methods This study was performed in three directions to understand the pandemic response of the two emerging variants. First, we served comparative genomics, such as genome sequence submission patterns, mutational landscapes, and structural landscapes of significant mutations (N501Y, D614G, L452R, E484Q, and P681R). Second, we performed evolutionary epidemiology using molecular phylogenetics, scatter plots of the cluster evaluation, country-wise transmission pattern, and frequency pattern. Third, the receptor binding pattern was analyzed using the Wuhan reference strain and the other two variants. Results The study analyzed the country-wise and region-wise genome sequences and their submission pattern, molecular phylogenetics, scatter plot of the cluster evaluation, country-wise geographical distribution and transmission pattern, frequency pattern, entropy diversity, and mutational landscape of the two variants. The structural pattern was analyzed in the N501Y, D614G L452R, E484Q, and P681R mutations. The study found increased molecular interactivity between hACE2-RBD binding of B.1.1.7 and B.1.617.2 compared to the Wuhan reference strain. Our receptor binding analysis showed a similar indication pattern for hACE2-RBD of these two variants. However, B.1.617.2 offers slightly better stability in the hACE2-RBD binding pattern through MD simulation than B.1.1.7. Conclusion The increased hACE2-RBD binding pattern of B.1.1.7 and B.1.617.2 might help to increase the infectivity compared to the Wuhan reference strain.
Collapse
|
59
|
Lino A, Cardoso MA, Martins‐Lopes P, Gonçalves HMR. Omicron - The new SARS-CoV-2 challenge? Rev Med Virol 2022; 32:e2358. [PMID: 35445774 PMCID: PMC9111063 DOI: 10.1002/rmv.2358] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2022] [Revised: 04/02/2022] [Accepted: 04/04/2022] [Indexed: 01/05/2023]
Abstract
SARS-CoV-2 virus has infected nearly 300 M people worldwide and has been associated with over 6 M deaths by March 2022. Since the virus emergence in December 2019 in Wuhan, several new mutations have been described. The World Health Organization has developed a working name for these emerging variants according to their impact on the worldwide population. In this context a high alert has been paid to variants of concern (VOC) due to their high infectiousness and transmissibility patterns. The most recent VOC, Omicron (B.1.1.529), has become dominant in the shortest time ever and has placed Europe under an overwhelming and unprecedented number of new cases. This variant has numerous mutations in regions that are associated with higher transmissibility, stronger viral binding, affinity and antibody escape. Moreover, the mutations and deletions present in the spike protein suggest that the SARS-CoV-2 specific attachment inhibitors may not be the best option for Omicron therapy. Omicron is the dominant variant circulating worldwide and, at the end of February 2022, it was responsible for nearly all sequences reported to GISAID. Omicron is made up of several sublineages, where the most common are BA.1 and BA.2 (or Nextstrain clade 21K and 21L, respectively). At a global level, it is possible to say that the proportion of BA.2 has been increasing relative to BA.1 and in some countries it has been replacing it at high rates. In order to better assess the Omicron effectiveness on antibody escape, spread and infectious ability it is of the highest relevance to maintain a worldwide tight surveillance. Even though this variant has been associated with a lower death rate, it is important to highlight that the number of people becoming infected is concerning and that further unpredictable mutations may emerge as the number of infected people rises.
Collapse
Affiliation(s)
- A. Lino
- BioISI ‐ Biosystems & Integrative Sciences InstituteFaculty of SciencesUniversity of LisbonLisbonPortugal
| | - M. A. Cardoso
- REQUIMTEInstituto Superior de Engenharia do PortoPortoPortugal
| | - P. Martins‐Lopes
- BioISI ‐ Biosystems & Integrative Sciences InstituteFaculty of SciencesUniversity of LisbonLisbonPortugal
- Department of Genetics and Biotechnology (DGB)University of Trás‐os‐Montes e Alto Douro (UTAD)Vila RealPortugal
| | | |
Collapse
|
60
|
Islam T, Hasan M, Rahman MS, Islam MR. Comparative evaluation of authorized drugs for treating Covid-19 patients. Health Sci Rep 2022; 5:e671. [PMID: 35734340 PMCID: PMC9194463 DOI: 10.1002/hsr2.671] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 04/22/2022] [Accepted: 05/08/2022] [Indexed: 12/15/2022] Open
Abstract
Background and Aims Vaccines are the first line of defense against coronavirus disease 2019 (Covid-19). However, the antiviral drugs provide a new tool to fight the Covid-19 pandemic. Here we aimed for a comparative evaluation of authorized drugs for treating Covid-19 patients. Methods We searched in PubMed and Google Scholar using keywords and terms such as Covid, SARS-CoV-2, Coronavirus disease 2019, therapeutic management, hospitalized Covid-19 patients, Covid-19 treatment. We also gathered information from reputed newspapers, web portals, and websites. We thoroughly observed, screened, and included the studies relevant to our inclusion criteria. We included only the United States Food and Drug Administration (FDA) authorized drugs for this review. Results We found that molnupiravir and paxlovid are available for oral use, and remdesivir is for only hospitalized patients. Paxlovid is a combination of nirmatrelvir and ritonavir, nirmatrelvir is a protease inhibitor (ritonavir increases the concentration of nirmatrelvir), and the other two (remdesivir and molnupiravir) are nucleoside analog prodrugs. Remdesivir and molnupiravir doses do not need to adjust in renal and hepatic impairment. However, the paxlovid dose adjustment is required for mild to moderate renal or hepatic impaired patients. Also, the drug is not allowed for Covid-19 patients with severe renal or hepatic impairment. Preliminary studies showed oral antiviral drugs significantly reduce hospitalization or death among mild to severe patients. Moreover, the US FDA has approved four monoclonal antibodies for Covid-19 treatment. Studies suggest that these drugs would reduce the risk of hospitalization or severity of symptoms. World Health Organization strongly recommended the use of corticosteroids along with other antiviral drugs for severe or critically hospitalized patients. Conclusion All authorized drugs are effective in inhibiting viral replication for most SARS-CoV-2 variants. Therefore, along with vaccines, these drugs might potentially aid in fighting the Covid-19 pandemic.
Collapse
Affiliation(s)
- Towhidul Islam
- Department of PharmacyUniversity of Asia PacificDhakaBangladesh
| | - Moynul Hasan
- Department of PharmacyJagannath UniversityDhakaBangladesh
| | | | | |
Collapse
|
61
|
Bellamkonda N, Lambe UP, Sawant S, Nandi SS, Chakraborty C, Shukla D. Immune Response to SARS-CoV-2 Vaccines. Biomedicines 2022; 10:1464. [PMID: 35884770 PMCID: PMC9312515 DOI: 10.3390/biomedicines10071464] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Revised: 05/27/2022] [Accepted: 05/30/2022] [Indexed: 12/21/2022] Open
Abstract
COVID-19 vaccines have been developed to confer immunity against the SARS-CoV-2 infection. Prior to the pandemic of COVID-19 which started in March 2020, there was a well-established understanding about the structure and pathogenesis of previously known Coronaviruses from the SARS and MERS outbreaks. In addition to this, vaccines for various Coronaviruses were available for veterinary use. This knowledge supported the creation of various vaccine platforms for SARS-CoV-2. Before COVID-19 there are no reports of a vaccine being developed in under a year and no vaccine for preventing coronavirus infection in humans had ever been developed. Approximately nine different technologies are being researched and developed at various levels in order to design an effective COVID-19 vaccine. As the spike protein of SARS-CoV-2 is responsible for generating substantial adaptive immune response, mostly all the vaccine candidates have been targeting the whole spike protein or epitopes of spike protein as a vaccine candidate. In this review, we have compiled the immune response to SARS-CoV-2 infection and followed by the mechanism of action of various vaccine platforms such as mRNA vaccines, Adenoviral vectored vaccine, inactivated virus vaccines and subunit vaccines in the market. In the end we have also summarized the various adjuvants used in the COVID-19 vaccine formulation.
Collapse
Affiliation(s)
- Navya Bellamkonda
- Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA;
| | | | - Sonali Sawant
- ICMR-NIV, Mumbai Unit, A. D. Road, Parel, Mumbai 400012, India; (U.P.L.); (S.S.)
| | - Shyam Sundar Nandi
- ICMR-NIV, Mumbai Unit, A. D. Road, Parel, Mumbai 400012, India; (U.P.L.); (S.S.)
| | | | - Deepak Shukla
- Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL 60612, USA
| |
Collapse
|
62
|
Yousaf Z, Khan MA, Asghar MS, Zaman M, Ahmed M, Tahir MJ. COVID-19 Omicron variant - Time for airborne precautions. Ann Med Surg (Lond) 2022; 78:103919. [PMID: 35693104 PMCID: PMC9166231 DOI: 10.1016/j.amsu.2022.103919] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Revised: 05/30/2022] [Accepted: 06/02/2022] [Indexed: 11/29/2022] Open
Abstract
Genetic mutations in SARS-CoV-2 have resulted in variants with more transmissibility and partial resistance to COVID-19 vaccines, as seen in the recently classified variant of concern (VOC) “Omicron”. The rapid spread has raised concerns about Omicron being airborne, which leads to a high risk of contamination in public premises, particularly among the frontline healthcare workers. Mandatory usage of protective face masks and respirators is highly recommended in order to break the chain of transmission. Furthermore, health authorities need to reassess the modes of transmission of VOCs and provide updated guidelines to the general public for its prevention.
Collapse
Affiliation(s)
| | - Muhammad Arslan Khan
- Department of Pharmaceutical Sciences, University of Lahore Teaching Hospital, Lahore, Pakistan
| | | | | | | | | |
Collapse
|
63
|
Li S, Gao Z, Zhong M, Yu Z, Li J, Bi H. Chinese University Students' Awareness and Acceptance of the COVID-19 Vaccine: A Cross-Sectional Study. Healthc Policy 2022; 15:845-864. [PMID: 35519502 PMCID: PMC9064172 DOI: 10.2147/rmhp.s360274] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Accepted: 04/16/2022] [Indexed: 12/12/2022] Open
Abstract
Purpose The emergence of the mutant virus has exacerbated the COVID-19 epidemic, and vaccines remain an effective and viable means of resistance. As a socially influential young group, university students’ awareness and acceptance of the COVID-19 vaccine are crucial to achieving herd immunity. This study aimed to assess the awareness and acceptance of the COVID-19 vaccine among Chinese university students and identify possible factors associated with their awareness level and vaccine hesitancy. Patients and Methods An anonymous cross-sectional survey was conducted among Chinese university students between 10 and 28 June 2021. We collected information on the demographic characteristics, awareness and acceptance of the COVID-19 vaccine, and influencing factors. Sleep disturbances and anxiety disorders were also evaluated. Multinomial logistic regression analyses were performed. Results Among the 721 participants (aged 18 to 23 years) with a female predominance (68.9%), 40.4% of cases exhibited moderate awareness the COVID-19 vaccine, and 87.4% of cases expressed high acceptance of the vaccine. Participants’ awareness of the COVID-19 vaccine was associated with gender, ethnicity, region of residence, grade level, satisfaction with current state of pandemic control, the perceived likelihood of a COVID-19 pandemic rebound, the source number of COVID-19 information, concerns about differences in vaccine manufacturers, acceptance of current state-approved vaccines and insomnia level. Furthermore, age, preferred channels for vaccination and the acceptance of current state-approved vaccines were significantly associated with their acceptance of the vaccine. Conclusion This study reflected Chinese university students’ high acceptance, but insufficient awareness of the COVID-19 vaccine, some students have insomnia and anxiety problems. These require the government to take measures such as individualized publicity and education, adding professional psychological counseling courses to improve the university students’ awareness of vaccines and public health events, and comprehensively promote vaccination to cope with the ever-changing situation of the COVID-19 epidemic.
Collapse
Affiliation(s)
- Shirui Li
- Department of Biostatistics, Xuzhou Medical University, Xuzhou, People's Republic of China
| | - Zhihui Gao
- Department of Biostatistics, Xuzhou Medical University, Xuzhou, People's Republic of China
| | - Meihan Zhong
- Department of Biostatistics, Xuzhou Medical University, Xuzhou, People's Republic of China
| | - Zhujun Yu
- Department of Biostatistics, Xuzhou Medical University, Xuzhou, People's Republic of China
| | - Jianan Li
- Key Laboratory of Environment and Health, Xuzhou Medical University, Xuzhou, People's Republic of China
| | - Haoran Bi
- Department of Biostatistics, Xuzhou Medical University, Xuzhou, People's Republic of China.,Center for Medical Statistics and Data Analysis, Xuzhou Medical University, Xuzhou, People's Republic of China.,Key Laboratory of Human Genetics and Environmental Medicine, Xuzhou Medical University, Xuzhou, People's Republic of China
| |
Collapse
|
64
|
Ding K, Jiang W, Xiong C, Lei M. Turning point: A new global COVID-19 wave or a signal of the beginning of the end of the global COVID-19 pandemic? Immun Inflamm Dis 2022; 10:e606. [PMID: 35349754 PMCID: PMC8962637 DOI: 10.1002/iid3.606] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Revised: 02/15/2022] [Accepted: 02/17/2022] [Indexed: 12/23/2022] Open
Abstract
A new variant named Omicron (B.1.1.529), first identified in South Africa, has become of considerable interest to the World Health Organization. This variant differs from the other known major variants, as it carries a large number of unusual mutations, particularly in the spinous process protein and receptor binding domains. Some specific mutation sites make it vaccine resistant, highly infectious, and highly pathogenic. The world fears that the Omicron variant could be even more harmful than the previous major variant, given that it has emerged amid fierce competition to trigger a new global pandemic peak as infections in South Africa rise. However, some epidemiological evidence has emerged that the Omicron variant may produce milder patient symptoms. We speculate if the virulence of the Omicron variant will diminish as transmissibility increases, thereby signaling the beginning of the end for the global COVID-19 pandemic. Based on this view, we make recommendations for COVID-19 mitigation in the present and future. However, it will take a few weeks to determine the true threat posed by the Omicron variant and we need to be fully prepared for future outbreaks, regardless of their severity.
Collapse
Affiliation(s)
- Kaixi Ding
- Hospital of Chengdu University of Traditional Chinese MedicineChengduChina
| | - Wei Jiang
- Hospital of Chengdu University of Traditional Chinese MedicineChengduChina
| | - Chunping Xiong
- Hospital of Chengdu University of Traditional Chinese MedicineChengduChina
| | - Ming Lei
- Hospital of Chengdu University of Traditional Chinese MedicineChengduChina
| |
Collapse
|
65
|
Obireddy SR, Guntakanti U, Kowthalam A, Marata Chinna Subbarao S, Lai WF. Omicron: Understanding the latest variant of SARS-CoV-2 and strategies for tackling the infection. Chembiochem 2022; 23:e202200126. [PMID: 35362644 PMCID: PMC9083820 DOI: 10.1002/cbic.202200126] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Revised: 03/31/2022] [Indexed: 11/24/2022]
Abstract
The new variant of concern of SARS‐CoV‐2, namely Omicron, has triggered global fear recently. To date, our knowledge of Omicron, particularly of how S glycoprotein mutations affect the infectivity of the virus and the severity of the infection, is far from complete. This hinders our ability to treat the disease and to predict the future state of SARS‐CoV‐2 threats to well‐being and economic stability. Despite this, efforts have been made to unveil the routes of transmission and the efficiency of existing vaccines in tackling Omicron. This article reviews the latest understanding of Omicron and the current status of the use of vaccines and drugs for infection control. It is hoped that this article can offer insights into the development of more effective measures to tackle the pandemic.
Collapse
Affiliation(s)
- Sreekanth Reddy Obireddy
- Sri Krishnadevaraya University, Chemistry, TIRUPATI NATIONAL HIGHWAY, ITUKALAPALLI, 515004, India, 515003, ANANTHAPURAMU, INDIA
| | | | | | | | - Wing-Fu Lai
- The Chinese University of Hong Kong, School of Life and Health Sciences, 518172, Shenzhen, CHINA
| |
Collapse
|
66
|
Temsah MH, Aljamaan F, Alenezi S, Alhasan K, Alrabiaah A, Assiri R, Bassrawi R, Alhaboob A, Alshahrani F, Alarabi M, Alaraj A, Alharbi NS, Halwani R, Jamal A, Al-Eyadhy A, AbdulMajeed N, Alfarra L, Almashdali W, Fayed A, Alzamil F, Barry M, Memish ZA, Al-Tawfiq JA, Alsubaie S. SARS-CoV-2 Omicron Variant: Exploring Healthcare Workers' Awareness and Perception of Vaccine Effectiveness: A National Survey During the First Week of WHO Variant Alert. Front Public Health 2022; 10:878159. [PMID: 35400032 PMCID: PMC8989964 DOI: 10.3389/fpubh.2022.878159] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Accepted: 03/01/2022] [Indexed: 12/21/2022] Open
Abstract
Background As the SARS-CoV-2 Omicron variant spreads in several countries, healthcare workers' (HCWs) perceptions and worries regarding vaccine effectiveness and boosters warrant reassessment. Methods An online questionnaire among HCWs in Saudi Arabia (KSA) was distributed from Dec 1st-6th 2021 to assess their perceptions, vaccine advocacy to the Omicron variant, and their perception of the effectiveness of infection prevention measures and vaccination to prevent its spread, their Omicron variant related worries in comparison to the other variants, and their agreement with mandatory vaccination in general for adults. Results Among the 1,285 HCW participants, two-thirds were female, 49.8 % were nurses, 46.4% were physicians, and 50.0% worked in tertiary care hospitals. 66.9% considered vaccination to be the most effective way to prevent the spread of the Omicron variant and future variants. The respondents however perceived social distancing (78.0%), universal masking (77.8%), and avoiding unnecessary travel (71.4%) as slightly superior to vaccination to prevent the spread of SARS-CoV-2 variants. HCWs aging 55 or older agreed significantly with vaccine ineffectiveness to control Omicron spread, while those who believed in non-pharmacological infection prevention measures agreed significantly with vaccination for that purpose. Male HCWs had a significant agreement with mandatory vaccination of all eligible adult populations. On the other hand, unwilling HCWs to receive the vaccine had strong disagreements with mandatory vaccination. Conclusions The current study in the first week of Omicron showed that only two-thirds of HCWs felt that vaccination was the best option to prevent the spread of the Omicron variant, indicating the need for further motivation campaigns for vaccination and booster dose. HCWs had a strong belief in infection prevention measures to contain the spread of SARS-CoV-2 variants that should be encouraged and augmented.
Collapse
Affiliation(s)
- Mohamad-Hani Temsah
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Department of Pediatric, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
- Department of Pediatrics, Faculty of Medicine, Prince Abdullah Ben Khaled Celiac Disease Research Chair, King Saud University, Riyadh, Saudi Arabia
| | - Fadi Aljamaan
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Department of Critical Care, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| | - Shuliweeh Alenezi
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Department of Psychiatry, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| | - Khalid Alhasan
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Department of Pediatric, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| | - Abdulkarim Alrabiaah
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Department of Pediatric, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| | - Rasha Assiri
- Department of Basic Medical Sciences, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
| | - Rolan Bassrawi
- Department of Pediatric, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| | - Ali Alhaboob
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Department of Pediatric, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| | - Fatimah Alshahrani
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Division of Infectious Diseases, Department of Internal Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| | - Mohammed Alarabi
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Department of Psychiatry, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| | - Ali Alaraj
- Department of Medicine, College of Medicine, Qassim University, Qassim, Saudi Arabia
- Dr. Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia
| | - Nasser S. Alharbi
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Department of Pediatric, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| | - Rabih Halwani
- Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates
- Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
| | - Amr Jamal
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Department of Family and Community Medicine, King Saud University Medical City, Riyadh, Saudi Arabia
| | - Ayman Al-Eyadhy
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Department of Pediatric, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| | - Naif AbdulMajeed
- Department of Pediatric, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
- Department of Pediatric Nephrology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Lina Alfarra
- Department of Ob-Gyn, Dr. Abdul Rahman Al Mishari Hospital, Riyadh, Saudi Arabia
| | - Wafa Almashdali
- Department of Ob-Gyn, Dr. Fatina Imran Medical Complex, Doha, Qatar
| | - Amel Fayed
- Department of Clinical Sciences, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia
| | - Fahad Alzamil
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Department of Pediatric, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| | - Mazin Barry
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Division of Infectious Diseases, Department of Internal Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
- Division of Infectious Diseases, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Ziad A. Memish
- King Saud Medical City, Ministry of Health and Alfaisal University, Riyadh, Saudi Arabia
- Hubert Department of Global Health, Emory University, Atlanta, GA, United States
| | - Jaffar A. Al-Tawfiq
- Department of Specialty Internal Medicine and Quality, Johns Hopkins Aramco Healthcare, Dhahra, Saudi Arabia
- Infectious Disease Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, United States
- Infectious Disease Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States
| | - Sarah Alsubaie
- College of Medicine, King Saud University, Riyadh, Saudi Arabia
- Department of Pediatric, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia
| |
Collapse
|
67
|
Islam MR. The SARS-CoV-2 Omicron (B.1.1.529) variant and the re-emergence of COVID-19 in Europe: An alarm for Bangladesh. Health Sci Rep 2022; 5:e545. [PMID: 35308422 PMCID: PMC8918917 DOI: 10.1002/hsr2.545] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 01/31/2022] [Accepted: 02/13/2022] [Indexed: 01/05/2023] Open
|
68
|
Mohapatra RK, Kuppili S, Kumar Suvvari T, Kandi V, Behera A, Verma S, Kudrat‐E‐Zahan, Biswal SK, Al‐Noor TH, El‐ajaily MM, Sarangi AK, Dhama K. SARS‐CoV‐2 and its variants of concern including Omicron: looks like a never ending pandemic. Chem Biol Drug Des 2022; 99:769-788. [PMID: 35184391 PMCID: PMC9111768 DOI: 10.1111/cbdd.14035] [Citation(s) in RCA: 29] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2021] [Revised: 02/12/2022] [Accepted: 02/16/2022] [Indexed: 12/15/2022]
Abstract
The ongoing COVID‐19 pandemic caused by SARS‐CoV‐2 is associated with high morbidity and mortality. This zoonotic virus has emerged in Wuhan of China in December 2019 from bats and pangolins probably and continuing the human‐to‐human transmission globally since last two years. As there is no efficient approved treatment, a number of vaccines were developed at an unprecedented speed to counter the pandemic. Moreover, vaccine hesitancy is observed that may be another possible reason for this never ending pandemic. In the meantime, several variants and mutations were identified and causing multiple waves globally. Now the safety and efficacy of these vaccines are debatable and recommended to determine whether vaccines are able to interrupt transmission of SARS‐CoV‐2 variant of concern (VOC). Moreover, the VOCs continue to emerge that appear more transmissible and less sensitive to virus‐specific immune responses. In this overview, we have highlighted various drugs and vaccines used to counter this pandemic along with their reported side effects. Moreover, the preliminary data for the novel VOC “Omicron” are discussed with the existing animal models.
Collapse
Affiliation(s)
- Ranjan K. Mohapatra
- Department of Chemistry Government College of Engineering Keonjhar‐758002 Odisha India
| | | | | | - Venkataramana Kandi
- Department of Microbiology Prathima Institute of Medical Sciences Karimnagar‐505417 Telangana India
| | - Ajit Behera
- Department of Metallurgical & Materials Engineering National Institute of Technology Rourkela‐769008 India
| | - Sarika Verma
- Council of Scientific and Industrial Research‐Advanced Materials and Processes Research Institute Bhopal MP 462026 India
- Academy of council Scientific and Industrial Research ‐ Advanced Materials and Processes Research Institute (AMPRI) Hoshangabad Road Bhopal (M.P) 462026 India
| | - Kudrat‐E‐Zahan
- Department of Chemistry Rajshahi University Rajshahi Bangladesh
| | - Susanta K. Biswal
- Department of Chemistry School of Applied Sciences Centurion University of Technology and Management Odisha India
| | - Taghreed H. Al‐Noor
- Chemistry Department Ibn‐Al‐Haithem College of Education for Pure Science Baghdad University Baghdad Iraq
| | - Marei M. El‐ajaily
- Chemistry Department Faculty of Science Benghazi University Benghazi Libya
| | - Ashish K. Sarangi
- Department of Chemistry School of Applied Sciences Centurion University of Technology and Management Odisha India
| | - Kuldeep Dhama
- Division of Pathology ICAR‐Indian Veterinary Research Institute Uttar Pradesh Bareilly India
| |
Collapse
|
69
|
Desingu PA, Nagarajan K. Omicron variant losing its critical mutations in the receptor-binding domain. J Med Virol 2022; 94:2365-2368. [PMID: 35181921 PMCID: PMC9088637 DOI: 10.1002/jmv.27667] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Revised: 02/14/2022] [Accepted: 02/16/2022] [Indexed: 11/07/2022]
Abstract
Recently the Omicron This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
| | - K Nagarajan
- Department of Veterinary Pathology, Madras Veterinary College, Vepery, Chennai, 600007, Tamil Nadu Veterinary and Animal Sciences University (TANUVAS)
| |
Collapse
|
70
|
Sienra Iracheta E, Mendez Sotelo BJ, Aranda Audelo M, Hernández Jeronimo JH, Villaseñor Martinez R, Martinez Oliva DH, Lopez Vejar C, Ramirez Hinojosa JP, Lopez Luis BA, Martínez Garcia J, Cervantes Villar LE, Matsumoto PMM, Rodriguez Zulueta AP. Outpatient surveillance programme for health workers with COVID 19 in Mexico: an observational study of ambulatory treatment and early hospitalization. Ther Adv Infect Dis 2022; 9:20499361221130212. [PMID: 36382138 PMCID: PMC9643119 DOI: 10.1177/20499361221130212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Accepted: 09/14/2022] [Indexed: 11/10/2022] Open
Abstract
Introduction: International guidelines recommend hospital care for patients with severe
Coronavirus disease (COVID-19), but fragile health care systems struggle to
cope with high number of admissions, placing patients at risk of receiving
substandard care. We describe an outpatient ambulatory surveillance and
treatment strategy (OPAT) for health care workers (HCWs) with severe
COVID-19 during low hospital bed availability periods in Mexico City. Methods: In this observational, descriptive, retrospective study, we included HCWs
with severe disease for whom there were no hospital beds available at the
time of evaluation. We provided daily assessments by infectious disease
specialists, daily ambulatory steroid, oral thromboprophylaxis and
domiciliary low-dose oxygen. We recorded the number of patients who
recovered, were hospitalized or died on follow-up. Results: From 18 March 2020 to 16 July 2021, 1739 HCWs attended our service. A total
of 540 were diagnosed with COVID-19. Seventy-four had severe COVID-19 and
needed hospitalization. Immediate hospitalization was not possible in 56
patients who were sent to the OPAT and included in our study. Twenty-four
patients subsequently required hospitalization and 32 recovered as
outpatients. Conclusions: We describe a feasible and safe outpatient management strategy for HCWs with
severe COVID-19 in a low-resource setting.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Luz Elena Cervantes Villar
- Instituto Nacional Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
- Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico
| | | | - Ana Patricia Rodriguez Zulueta
- Hospital General Dr. Manuel Gea Gonzalez, Mexico city, Mexico
- Hospital General Dr. Manuel Gea Gonzalez, Mexico City, Mexico
| |
Collapse
|
71
|
Rabiul Islam M, Nasreen W, Anjum R, Shahriar M, Roy A, Dhama K, Ahmed Bhuiyan M. Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health. CLINICAL PATHOLOGY (THOUSAND OAKS, VENTURA COUNTY, CALIF.) 2022; 15:2632010X221124908. [PMID: 36147794 PMCID: PMC9490387 DOI: 10.1177/2632010x221124908] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Accepted: 08/22/2022] [Indexed: 01/07/2023]
Abstract
The discovery of the SARS-CoV-2 Omicron (B.1.1.529) variant has sparked alarm globally because of its rapid rate of infection and trespassing acquired immunity due to vaccination or natural infection. This heavily mutated variant is rapidly spreading around the world. Infected individuals with the Omicron variant may suffer from flu-like symptoms, and infected with the Delta variant frequently report low oxygen levels, high pulse rates, and a loss of smell and taste. Also, the Omicron variant causes asymptomatic or mild disease so far, and not any severe illness as like Delta, and this new variant has a 15% to 80% reduced risk of hospitalization than the Delta variant. Scientists are worried about the possibility of escaping the immunity by the Omicron variants and subvariants among fully vaccinated and recovered COVID-19 patients. Two doses of available vaccines are found to be partially ineffective in protecting this new variant, therefore, the third dose as a booster is recommended to enhance antibody level. Moreover, some antiviral drugs significantly reduce hospitalization or death among mild to severe COVID-19 patients. All authorized antiviral drugs are effective against viral replication for most SARS-CoV-2 variants, and particularly some monoclonal antibodies may not now be effective in treating COVID-19 patients. There is an urgent need to update existing vaccines, develop more effective and newer vaccines as well as additional monoclonal antibodies to counter Omicron. Therefore, along with close monitoring of Omicron characteristics, the present study suggests that health safety guidelines, mass immunization, early diagnosis, and search for effective antiviral drugs should be the approaches to fight against newer SARS-CoV-2 variants.
Collapse
Affiliation(s)
- Md. Rabiul Islam
- Department of Pharmacy, University of
Asia Pacific, Dhaka, Bangladesh
| | - Waheeda Nasreen
- Department of Pharmacy, University of
Asia Pacific, Dhaka, Bangladesh
| | - Ramisa Anjum
- Department of Pharmacy, University of
Asia Pacific, Dhaka, Bangladesh
| | - Mohammad Shahriar
- Department of Pharmacy, University of
Asia Pacific, Dhaka, Bangladesh
| | - Arpita Roy
- Department of Biotechnology, School of
Engineering & Technology, Sharda University, Greater Noida, India
| | - Kuldeep Dhama
- Division of Pathology, ICAR-Indian
Veterinary Research Institute, Bareilly, India
| | | |
Collapse
|
72
|
Daria S, Islam MR. Indiscriminate Use of Antibiotics for COVID-19 Treatment in South Asian Countries is a Threat for Future Pandemics Due to Antibiotic Resistance. CLINICAL PATHOLOGY (THOUSAND OAKS, VENTURA COUNTY, CALIF.) 2022; 15:2632010X221099889. [PMID: 35601922 PMCID: PMC9121502 DOI: 10.1177/2632010x221099889] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Accepted: 04/24/2022] [Indexed: 12/18/2022]
Abstract
The COVID-19 pandemic has put enormous strain on the global public health and healthcare systems. Here we aimed to assess the prevalence and impact of indiscriminate use of antibiotics for COVID-19 treatment in south Asian countries. We observed the indiscriminate use of antibiotics in south Asian countries and other similar parts of the world. Along with vaccines, people in poor and developing countries have been taking antibiotics and some other medications without proper jurisdiction during the waves of the COVID-19 pandemic. We all know that COVID-19 is a viral disease, and only a few patients might have bacterial co-infections. Therefore, the role of antibiotics is ambiguous in most COVID-19 cases. Consequently, the overuse of antibiotics would cause antimicrobial resistance that has the potential to become a 2-edged sword after the COVID-19 pandemic era. Our findings emphasize the judicious use of antibiotics in COVID-19 therapy, especially in poor and developing countries across the globe.
Collapse
Affiliation(s)
- Sohel Daria
- Department of Pharmacy, University of Asia
Pacific, Farmgate, Dhaka, Bangladesh
| | - Md. Rabiul Islam
- Department of Pharmacy, University of Asia
Pacific, Farmgate, Dhaka, Bangladesh
| |
Collapse
|
73
|
Rahman S, Hossain MJ, Islam MR. The Upsurge of Diarrhea Amid COVID-19 Pandemic Makes Matter Worse in Bangladesh: A Call to Action. Gerontol Geriatr Med 2022; 8:23337214221117419. [PMID: 35966641 PMCID: PMC9364194 DOI: 10.1177/23337214221117419] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 07/03/2022] [Accepted: 07/10/2022] [Indexed: 12/24/2022] Open
Abstract
We have seen an alarming increase in diarrhea prevalence amid Coronavirus
Disease-2019 (COVID-19) in Bangladesh. Healthcare professionals might
face difficulty in diagnosis as these two infectious diseases have
some common symptoms. Though there are confirmatory diagnostic tests
for individual cases, there are chances of misdiagnosis as
co-infections occur. Here we presented distinct clinical features of
diarrhea and COVID-19 for differential diagnosis. We demonstrated the
common overlapping symptoms of these two infectious diseases to
facilitate fast diagnosis of patients. Also, we have discussed
possible reasons for this upsurge of diarrheal infections in
Bangladesh. Finally, we have made some recommendations based on our
findings for managing this upsurge of diarrheal disease during the
COVID-19 pandemic in Bangladesh. The healthcare authorities should
take immediate measures before the tremendous twin effects of these
two infectious diseases.
Collapse
|